Development of RNA Methyltransferase Inhibitors as Therapeutics for SARS-CoV2 and Future Pandemic Preparedness

RNA 甲基转移酶抑制剂的开发作为 SARS-CoV2 的治疗药物和未来大流行的防范

• 批准号: 10025895
• 金额: $ 89.15万
• 依托单位: STORM THERAPEUTICS LIMITED
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2022
• 资助国家: 英国
• 起止时间: 2022 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=10025895
• 关键词: Development; RNA; Methyltransferase; Inhibitors; Therapeutics

The Covid-19 pandemic has caused unprecedented damage to global health, society and economies. The development of successful vaccines has had a major impact but the dangers of the pandemic remain due the challenges of vaccinating the whole population and that protection given by vaccination reduces over time. In addition, there remains an ongoing risk that new virus variants emerge which the vaccine does not protect against. It is therefore important that society develops a suite of drugs against Covid-19 to treat infected individuals as part of the wider pandemic efforts.This project aims to develop a drug against a Covid-19 protein to which no current drugs exist. Generation of such a drug will provide another approach to treating Covid-19 which can be used alongside existing approaches to treat infected patients or to treat patients which become resistant to current drugs. The drug that we plan to develop could also be effective against other viruses from the Covid family and could be used provide a treatment for patients during the time taken to develop a new vaccine against a new Covid family virus outbreak.Storm is the leading company working on this type of Covid protein and hence is well placed to develop this drug and contribute to the global pandemic efforts and to protecting society from future outbreaks.

新型冠状病毒疫情对全球健康、社会和经济造成了前所未有的破坏。研制成功的疫苗产生了重大影响，但大流行病的危险仍然存在，这是由于为全体人口接种疫苗的挑战以及疫苗接种提供的保护随着时间的推移而减少。此外，仍然存在出现疫苗无法预防的新病毒变体的持续风险。因此，作为更广泛的大流行努力的一部分，社会开发一套针对COVID-19的药物来治疗感染者是很重要的。该项目旨在开发一种针对COVID-19蛋白的药物，目前还没有针对这种蛋白的药物。这种药物的产生将提供另一种治疗Covid-19的方法，可以与现有方法一起用于治疗感染患者或治疗对当前药物产生耐药性的患者。我们计划开发的药物也可以有效对抗新冠病毒家族的其他病毒，并可以在开发新疫苗以对抗新冠病毒家族病毒爆发的时间内为患者提供治疗。Storm是研究这类新冠病毒蛋白的领先公司，因此有能力开发这种药物，为全球大流行努力做出贡献，并保护社会免受未来的威胁。爆发